⌕

Moderna (MRNA) vs Takeda Pharmaceutical (TAK)

Your goal
● Balanced style: every factor counts equally.
#1 FIT · LEADS
62
Takeda Pharmaceutical Co
$21.43 · $74B · as of last close
Calmest rideBest incomeBest returns
of the stocks compared here

The front-runner. Leads the balanced score. Its widest win over the field is risk (calm = better).

#2 FIT
32
Moderna Inc
$223.37 · $90B · as of last close

The challenger. Trails the leader on the balanced score. Its widest win over the field is balance sheet.

TAK leads clearly (62/100 vs MRNA 32) under a balanced style, mostly on risk (calm = better). But MRNA wins on balance sheet, so the comparison turns on what you weight. Switch your goal above and watch the scores move.

THE SCORECARD · FACTOR BY FACTOR · the best value in each row is ticked, and a tie ticks every tied column · weight bar shows how much it counts for your goal

FactorMRNATAK
Overall fit score
weighted for your balanced goal
32
7 of 8 factors known
✓ 62
Valuation
Cheaper for what you get
1×
P/E —
13
✓ P/E — · EV/EBITDA 25.5
fiscal 2026
44
Growth
Revenue & earnings momentum
1×
✓ —
38
—
37
Profitability & quality
Margins & return on capital
1×
Net −110% · ROIC −28%
TTM through Sep 30, 2026
30
✓ Net −3% · ROIC 0%
fiscal 2026
37
Total return
Share-price change with dividends reinvested
1×
5Y −1%/yr
46
✓ 5Y +13%/yr
76
Risk (calm = better)
Volatility & drawdown
1×
β 1.5 · DD −94%
4
✓ β 0.2 · DD −23%
99
Balance sheet†
Debt vs cash cushion
1×
✓ Current ratio 3.62
Sep 30, 2026 balance sheet
53
Net debt/EBITDA 6.9×
fiscal 2026
9
Dividend & income
Cash paid to you
1×
—
40
✓ 2.94% yield· D
97
Analyst sentiment
Forward EPS growth (consensus)
1×
no forward consensus
—
✓ Est EPS +57%/yr · 3 analysts
100
† Balance sheet is scored on 5 peer percentiles (current ratio, quick ratio, net debt/EBITDA, interest coverage and debt/equity). The cell shows one of them, so a column can lead on the printed number and still lose the row.
The letter beside the dividend yield is our dividend-safety grade (A+ to F), a read on how likely that dividend is to be cut. It does not grade the yield.
Loading chart…
WHERE EACH ONE IS STRONG
GrowthValueQualityReturnSafetyIncome
■ MRNA■ TAK
CAN YOU STOMACH THE RIDE?
Worst drawdown3-year beta vs S&P 500VolatilityHistory
MRNA−94%1.54104%5Y
TAK−23%0.1719%5Y
Drawdown and volatility are measured over five years on the same total return as the chart, dividends reinvested.
THE CASE FOR & AGAINST EACH
BULL CASE

▲ Best factor is balance sheet: Current ratio 3.62 (score 53).

BEAR CASE

▼ Weakest on risk (calm = better): β 1.5 · DD −94% (score 4).

▼ Weakest on dividend & income: — (score 40).

BULL CASE

▲ Leads on risk (calm = better): β 0.2 · DD −23% (score 99).

▲ Leads on dividend & income: 2.94% yield (score 97).

BEAR CASE

▼ Weakest on balance sheet (score 9). Net debt/EBITDA 6.9× is one of the 5 inputs.

▼ Weakest on growth: — (score 37).

WHAT COULD CHANGE THE SCORE
Risk (calm = better)Currently 4/100 (β 1.5 · DD −94%). Taking it to 100 would lift the balanced score by 14 points, the biggest single move available.
ValuationCurrently 13/100 (P/E —). Taking it to 100 would lift the balanced score by 12 points, the next biggest.
Balance sheetCurrently 9/100 (Net debt/EBITDA 6.9×). Taking it to 100 would lift the balanced score by 12 points, the biggest single move available.
GrowthCurrently 37/100 (—). Taking it to 100 would lift the balanced score by 8 points, the next biggest.
Scores are Tenet composites, 0–100, reweighted for your selected goal. Seven of the eight factors are sector percentiles; analyst sentiment is an absolute curve on forward EPS growth, capped at 100, so two very high-growth names can share the top score. Moat/durability is not scored (qualitative, not measurable). Comparison is decision-support, not a recommendation · past performance does not predict future returns · Not investment advice · prices are each company's own latest close, the newest here being Nov 13, 2026 · valuation, growth, quality and balance scores from the Nov 13, 2026 scoring run · analyst consensus, return, risk and income scores computed Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.